{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:10:58Z","timestamp":1793232658024,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.urolonc.2023.08.012","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T20:32:16Z","timestamp":1694291536000},"page":"486.e1-486.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta\/T1 urothelial carcinoma before and after BCG treatment"],"prefix":"10.1016","volume":"41","author":[{"given":"Aziz Hakk\u0131","family":"Civriz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerem","family":"Teke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enes Malik","family":"Akdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozdal","family":"Dillioglugil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cigdem","family":"Vural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-3127","authenticated-orcid":false,"given":"Busra","family":"Yaprak Bayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2023.08.012_bib0001","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2023.08.012_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2023.08.012_bib0003","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2023.08.012_bib0004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/PAP.0000000000000050","article-title":"Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates","volume":"22","author":"Solomon","year":"2015","journal-title":"Adv Anat Pathol"},{"issue":"6","key":"10.1016\/j.urolonc.2023.08.012_bib0005","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00345-019-02896-3","article-title":"Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC)","volume":"38","author":"Delcourt","year":"2020","journal-title":"World J Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2023.08.012_bib0006","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.7150\/ijbs.54442","article-title":"USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway","volume":"17","author":"He","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2023.08.012_bib0007","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10353-021-00700-4","article-title":"Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy","volume":"53","author":"Jomrich","year":"2021","journal-title":"Eur Surg"},{"key":"10.1016\/j.urolonc.2023.08.012_bib0008","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/251479","article-title":"Immunohistochemical analysis of IL-6, IL-8\/CXCR2 axis, \u2009Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: correlation between microvascular characteristics and prognostic significance","volume":"2014","author":"Levidou","year":"2014","journal-title":"Biomed Res Int"},{"issue":"15","key":"10.1016\/j.urolonc.2023.08.012_bib0009","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.3390\/ijms23158133","article-title":"Multiparametric classification of non-muscle invasive papillary urothelial neoplasms: combining morphological, phenotypical, and molecular features for improved risk stratification","volume":"23","author":"Montes-Mojarro","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.urolonc.2023.08.012_bib0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2023.08.012_bib0011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11912-021-01091-1","article-title":"Approaches to non-muscle-invasive bladder cancer","volume":"23","author":"Slovacek","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.urolonc.2023.08.012_bib0012","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s00345-019-03065-2","article-title":"Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy","volume":"38","author":"Aydin","year":"2020","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2023.08.012_bib0013","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.urolonc.2023.08.012_bib0014","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1464-410X.2010.10020.x","article-title":"FOXP3 and survival in urinary bladder cancer","volume":"108","author":"Winerdal","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2023.08.012_bib0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.humpath.2019.04.003","article-title":"Tumor immune microenvironment in non\u2013muscle-invasive urothelial carcinoma of the bladder","volume":"89","author":"Eich","year":"2019","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2023.08.012_bib0016","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urolonc.2016.10.004","article-title":"A review of the PD-1\/PD-L1 checkpoint in bladder cancer: from mediator of immune escape to target for treatment","volume":"35","author":"Zhou","year":"2017","journal-title":"Urol Oncol"},{"issue":"28","key":"10.1016\/j.urolonc.2023.08.012_bib0017","doi-asserted-by":"crossref","first-page":"26065","DOI":"10.18632\/oncotarget.4569","article-title":"Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8\/androgen receptor (AR)\/MMPs signals","volume":"6","author":"Ou","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.urolonc.2023.08.012_bib0018","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cas.13887","article-title":"Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder","volume":"110","author":"Wang","year":"2019","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.urolonc.2023.08.012_bib0019","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdv009","article-title":"Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma","volume":"26","author":"Bellmunt","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2023.08.012_bib0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-017-0299-1","article-title":"Biomarkers for immunotherapy in bladder cancer: a moving target","volume":"5","author":"Aggen","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2023.08.012_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.527385","article-title":"PD-L1 expression in muscle-invasive urinary bladder urothelial carcinoma according to basal\/squamous-like phenotype","volume":"10","author":"Kim","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2023.08.012_bib0022","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"22","key":"10.1016\/j.urolonc.2023.08.012_bib0023","doi-asserted-by":"crossref","first-page":"690","DOI":"10.21037\/atm.2019.10.24","article-title":"PD-L1 assessment in urothelial carcinoma: a practical approach","volume":"7","author":"Eckstein","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.urolonc.2023.08.012_bib0024","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.humpath.2019.05.003","article-title":"PD-L1 expression in non\u2013small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays","volume":"90","author":"Munari","year":"2019","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.urolonc.2023.08.012_bib0025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/annonc\/mdy014","article-title":"Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer","volume":"29","author":"Adam","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2023.08.012_bib0026","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.urolonc.2023.08.012_bib0027","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1602460","article-title":"Combined assessment of peritumoral Th1\/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC","volume":"8","author":"Mart\u00ednez","year":"2019","journal-title":"Oncoimmunology"},{"issue":"75","key":"10.1016\/j.urolonc.2023.08.012_bib0028","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.urolonc.2023.08.012_bib0029","doi-asserted-by":"crossref","first-page":"603.e9","DOI":"10.1016\/j.urolonc.2020.01.001","article-title":"Programmed death-ligand 2 (PD-L2) expression in bladder cancer","volume":"38","author":"Yang","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.08.012_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2020.05.010","article-title":"Clinical relevance and prognostic significance of PD-1\/PD-Ls in non-metastatic bladder cancer: a role for PD-L2","volume":"124","author":"Ariafar","year":"2020","journal-title":"Mol Immunol"},{"issue":"13","key":"10.1016\/j.urolonc.2023.08.012_bib0031","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.7150\/thno.41498","article-title":"ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma","volume":"10","author":"Tong","year":"2020","journal-title":"Theranostics"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923002831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923002831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:28:20Z","timestamp":1761042500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923002831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1078143923002831"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.08.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta\/T1 urothelial carcinoma before and after BCG treatment","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}